Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer
- PMID: 2166720
- DOI: 10.1007/BF00177255
Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer
Abstract
Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical